Virtual Library

Start Your Search

Y. Miyagi



Author of

  • +

    P2.18 - Poster Session 2 - Pathology (ID 176)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Pathology
    • Presentations: 1
    • +

      P2.18-019 - Clinicopathological features in non-small cell lung cancer patients with EGFR and KRAS mutations. (ID 2985)

      09:30 - 09:30  |  Author(s): Y. Miyagi

      • Abstract

      Background
      Some of molecular pathways have been shown to have prognostic impact in non-small cell lung cancer (NSCLC). Epidermal growth factor receptor (EGFR) mutations predict the effect of EGFR tyrosine kinase inhibitors. KRAS is also critical oncogene, and it has been reported that KRAS pathway might interact with EGFR. But, the role of KRAS in NSCLC is unclear. We investigated the relationship between EGFR and KRAS mutation status and clinicopathological features in NSCLC.

      Methods
      A total of 383 consecutive patients with NSCLC underwent complete resection from 2006 to 2008 were examined retrospectively. The expression of EGFR and KRAS were evaluated by tissue microarray.

      Results
      The mutations of EGFR and KRAS were detected in 181/383 (47.3%) and 32/383 (8.4%) patients, respectively. On analysis of EGFR mutations, female were 107/181 (59.1%) and 51/202 (25.2%), adenocarcinoma were 177/181 (97.8%) and 123/202 (60.9%), no vascular invasion were 147/181 (81.2%) and 110/202 (54.5%), and non-smoker were 99/181 (54.7%) and 41/202 (20.3%) patients in EGFR mutation and wild type patients, respectively. As a result, EGFR mutation was found more frequently in female, adenocarcinoma, no vascular invasion, and non-smoker. The number of patients with pathological T1a were 49/181 (27.0%) and 42/202 (20.8%), T1b were 63/181 (34.8%) and 41/202 (20.3%) in EGFR mutation and wild type patients, respectively. Moreover, average tumor diameter was smaller in patients with EGFR mutation (2.68 cm±0.92) than wild type (3.34cm±1.70) (P<0.001). There were no differences in clinicopathological characteristics between exon19 and 21 EGFR mutations. In contrast, there were no significant differences between KRAS mutation and gender, histopathological type, vascular invasion and.smoking. Although KRAS status was not correlated with pathological T factors, average tumor diameter was larger in patients with KRAS mutation (3.49 cm±2.00) than wild type (2.98 cm±1.35) (P<0.001).

      Conclusion
      Our results suggest that EGFR mutation may suppress vascular invasion, and tumor growth, on the other hand, KRAS mutation may correlate with activation of tumor growth.

  • +

    P3.19 - Poster Session 3 - Imaging (ID 181)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Imaging, Staging & Screening
    • Presentations: 1
    • +

      P3.19-010 - The Status of EGFR Mutations in Mixed Ground-Glass Opacity (part-solid GGO) on Thin-section CT (ID 1826)

      09:30 - 09:30  |  Author(s): Y. Miyagi

      • Abstract

      Background
      Thin-section CT (TS-CT) provides us with a more precise image of small pulmonary carcinomas. Thin-slice sections with thicknesses of 0.5 mm-1mm reflect, with some accuracy, the histopathological findings; mixed ground-glass opacity (part-solid GGO) is one characteristic finding of pulmonary adenocarciomas. These findings are vary in appearance, for example; some contain mainly GGO components, and some contain mainly solid portions. CT findings of mixed GGO, pathological findings and prognoses have been reported. Presently, we do not fully understand the correlation between TS-CT findings of mixed GGO and the status of EGFR mutation.

      Methods
      We retrospectively reviewed the records and TS-CT scans of 115 patients with mixed GGO tumors. All patients had undergone surgical resection between 2002 and 2008. Tumor diameters measured 20mm or less in size. All TS-CT images were acquired by Aquillion CT scanner (Toshiba Medical System). TS-CT images of tumors were obtained at 135kVp at 250mAs with 0.5-1mm section thickness. All images were photographed using mediastinal (level, 40HU; width, 400HU) and lung (level, -600HU); width, 1600HU) window settings. All TS-CT images on lung window setting were classified as: (1) Predominant GGO type (pGGO; solid portion areas less than 50% of tumor), (2) Heterogeneous type (heterogenous increased density), (3) Predominat solid type (pSolid; Solid portion areas took up more than 50% of tumor). We analyzed EGFR and Kras mutations, and then studied the correlations between these TS-CT findings and the status of EGFR mutations.

      Results
      The tumors in all 115 cases were well-differentiated adenocarcinomas. GwS type; 24 cases, Heteogenous type; 30 cases, and SwG type 61 cases. The EGFR mutation ratio was 66.6% in pGGO type, 90% in Heterogenous type and 52.7% in pSolid type. The ratio of EGFR mutation was greater in Heterogenous types compared to pGGO and pSolid types. (pGGO/Hetero p=0.045, pSolid/Hetero p=0.00038).

      Conclusion
      There is a correlation between the thin-section findings of mixed GGO and the status of EGFR mutations.